After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Valued at a market cap of $10.8 billion, Viatris Inc. (VTRS) is a healthcare company headquartered in Canonsburg, ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Viatris has aggressively deleveraged, now poised for growth with a robust pipeline. See why a Strong Buy rating is justified ...

Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess ...

Viatris looks to boast a safe dividend and decent balance sheet. So, should investors buy the stock? Well, the stock is trading at a forward price-to-earnings (P/E) ratio of 4.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...